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OBJECTIVES This study compared a biphasic waveform with a conventional monophasic waveform for
cardioversion of atrial fibrillation (AF).
BACKGROUND Biphasic shock waveforms have been demonstrated to be superior to monophasic shocks for
termination of ventricular fibrillation, but data regarding biphasic shocks for conversion of AF
are still emerging.
METHODS In an international, multicenter, randomized, double-blind clinical trial, we compared the
effectiveness of damped sine wave monophasic versus impedance-compensated truncated
exponential biphasic shocks for the cardioversion of AF. Patients received up to five shocks,
as necessary for conversion: 100 J, 150 J, 200 J, a fourth shock at maximum output for the
initial waveform (200 J biphasic, 360 J monophasic) and a final cross-over shock at maximum
output of the alternate waveform.
RESULTS Analysis included 107 monophasic and 96 biphasic patients. The success rate was higher for
biphasic than for monophasic shocks at each of the three shared energy levels (100 J: 60% vs.
22%, p 0.0001; 150 J: 77% vs. 44%, p 0.0001; 200 J: 90% vs. 53%, p 0.0001). Through
four shocks, at a maximum of 200 J, biphasic performance was similar to monophasic
performance at 360 J (91% vs. 85%, p 0.29). Biphasic patients required fewer shocks (1.7
1.0 vs. 2.8  1.2, p  0.0001) and lower total energy delivered (217  176 J vs. 548  331 J,
p  0.0001). The biphasic shock waveform was also associated with a lower frequency of
dermal injury (17% vs. 41%, p  0.0001).
CONCLUSIONS For the cardioversion of AF, a biphasic shock waveform has greater efficacy, requires fewer
shocks and lower delivered energy, and results in less dermal injury than a monophasic shock
waveform. (J Am Coll Cardiol 2002;39:1956–63) © 2002 by the American College of
Cardiology Foundation
Atrial fibrillation (AF) is the most common arrhythmia
requiring treatment and is expected to increase in frequency
as the population ages (1–4). Transthoracic cardioversion is
an important component of AF treatment. Traditionally,
cardioversion used monophasic shocks, primarily with a
damped sine waveform. Monophasic shocks are limited by
failure to convert, typically occurring around 10% of the
time (5–7) but ranging up to 20% (8) or 30% (9), depending
on technique and patient population characteristics. Tech-
niques to increase cardioversion success have included ma-
neuvers such as alternate electrode placement (10), com-
pression on the electrodes (11) and simultaneous shocks
from two defibrillators (12). Ibutilide infusion before shock
has shown promise in raising the success rate to 100%
(13,14), although it carries a proarrhythmic risk. The
limitations of monophasic shocks, and the success of the
biphasic waveform for internal and external cardioversion of
ventricular fibrillation, led to the development of biphasic
cardioversion of AF. Ricard et al. (7) and Mittal et al. (8)
have published reports of improved cardioversion of AF
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with biphasic waveform. We present the results of a
multicenter, randomized, double-blind, international trial
comparing monophasic and biphasic waveform shocks for
the conversion of AF.
METHODS
Entry criteria. Patients enrolled were 18 years or older,
hemodynamically stable and scheduled for elective cardio-
version of AF. Exclusion criteria were epicardial defibrillator
electrodes, pacemaker dependence, participation in a
double-blind antiarrhythmic trial, dependence on vasopres-
sors or inability to place defibrillation electrodes in the
positions defined by the study.
Proper anticoagulation for AF of 48 h duration was
required, as defined by either three weeks with international
normalized ratio 2.0 or intravenous heparin with trans-
esophageal echocardiogram (15) negative for left atrial (LA)
thrombus; anticoagulation was required for the four weeks
after cardioversion. For AF known to be of 48 h duration,
no specific prior anticoagulation protocol was required.
Study protocol. Atrial fibrillation was defined by absence
of organized atrial activity, presence of AF waves and
irregularly irregular ventricular activity.
Identical cardioversion electrodes were used for all pro-
cedures, measuring 10.6 cm  15.8 cm. The posterior
electrode was placed to the right of the patient’s spine at the
midscapular level, while the anterior electrode was placed to
the left of the sternum with its upper edge at the level of the
fourth anterior intercostal space.
Anesthesia method was at the discretion of the individual
institution, although propofol was recommended.
Electrocardiographic (ECG) data were obtained from a
12-lead ECG before the procedure and a multichannel
rhythm strip, a three-lead Holter monitor (model 20/20D,
Phillips Medical Systems, Zymed, Oxnard, California) and
the defibrillator recorder during the procedure.
The defibrillators were outwardly identical other than for
the serial number. The monophasic device was a standard
unit (CodeMaster XL M1722B, Hewlett Packard, Palo
Alto, California), with modified labeling so the investigator
could not determine from the energy labeling which shock
waveform was being administered. The biphasic device
contained circuitry to deliver an impedance-compensated
biphasic shock waveform (same as the Heartstream XL
M4735A [Philips Medical Systems, Seattle, Washington],
then in development). The waveforms are shown in Figure
1. The devices were labeled at four energy levels: 100 J,
150 J, 200 J and 200/360 J. The final level either delivered
a repeat shock of 200 J biphasic or provided 360 J monopha-
sic. Both devices provided an impedance measurement for
each shock.
Study procedures. The study was approved by the respec-
tive institutional review boards, and informed consent was
obtained from each patient. The two defibrillators were
placed side by side on a cart. Randomization by sealed
envelope was used to determine which device would be
placed, out of the view of the investigator, on the left of the
cart—the location used for all cardioversion attempts before
crossover.
All shocks were synchronized to the QRS complex on the
surface ECG. Up to five shocks were delivered per protocol.
The first four shocks were delivered by the assigned device,
with progression from 100 J, 150 J, 200 J and then either
200 J biphasic or 360 J monophasic. If these four shocks
were ineffective, the patient crossed over to the alternative
device at maximum shock output (200 J biphasic or 360 J
monophasic).
The protocol was terminated by conversion to another
rhythm or by completion of the five-shock sequence. Sub-
sequent therapy was at the investigator’s discretion, using
standard equipment. Successful conversion was defined by
two consecutive P waves uninterrupted by AF occurring any
time within 30 s of the shock. If the shock resulted in atrial
flutter or atrial tachycardia that required further interven-
tion, the protocol was terminated and the shock was not
counted as a success.
Skin burns, common after monophasic waveform shocks
(16), were assessed 24 h to 48 h after the procedure, by
either direct inspection or telephone interview. A prospec-
tively defined scale was employed, defining burn as: none;
Abbreviations and Acronyms
AF  atrial fibrillation
ANOVA  analysis of variance
ECG  electrocardiogram/electrocardiographic
LA  left atrial
NYHA  New York Heart Association
Figure 1. Shock waveforms used in the study, across a 77 ohm resistance.
This represents the median transthoracic impedance observed in the study.
A monophasic damped sine (MDS) waveform (solid line) was compared
with a biphasic truncated exponential (BTE) waveform (dashed line).
Dashed line  BTE (150 J); solid line  MDS (150 J).
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mild (erythema, no tenderness); moderate (erythema, ten-
derness) or severe (blistering or necrosis, tenderness). The
investigators remained blinded to the waveform used
throughout the study.
Data analysis. The study was powered to detect a differ-
ence of 20% in first shock (100 J) efficacy, in a two-tailed
fashion, with a confidence level of 95% and power of 80%.
This called for 94 patients in each arm. To allow for errors
in enrollment and patient drop-out, a target of 105 patients
per arm was chosen.
A data and safety monitoring board reviewed the progress
monthly, blinded to treatment until six months, when they
assessed for justification of early termination in an un-
blinded fashion. There were no safety concerns nor were
criteria for early termination met, so the trial was completed.
All ECG rhythms were reviewed by an event committee
of two cardiac electrophysiologists who resolved discrepan-
cies by consensus. ST segments after successful shocks were
measured by one cardiac electrophysiologist from digital
ambulatory ECG recorders (20/20D recorders, Philips
Medical Systems, Zymed, Oxnard, California). All ECG
review was blinded as to treatment.
Statistical analysis. Binary counts were evaluated with
Fisher exact test, multiple alternative counts with the
Fisher-Freeman-Halton test, using StatXact, version 4.0.1
(Cytel Software, Cambridge, Massachusetts), which also
calculated the adjusted relative risks and their exact 95%
confidence intervals. Other statistical tests were performed
with Statistica, version 5.5 (StatSoft, Tulsa, Oklahoma).
Ordinal data and non-Gaussian continuous data (checked
with the Shapiro-Wilks W test) were evaluated with non-
parametric Kruskal-Wallis analysis of variance (ANOVA).
Other continuous data were evaluated by ANOVA. Multi-
variate analysis of binomial outcomes, under logistic trans-
formation, was performed on mixed categorical and contin-
uous variables using a generalized linear/nonlinear model
with stepwise backward removal on the basis of the Wald
statistic with a retention criterion of p  0.05. Significance
criteria in multiple sets of analyses (post-shock rhythms, ST
levels) were adjusted by the Bonferroni method.
Table 1. Patient Characteristics and Clinical Demographic Data
Count (%) or Mean  SD (range)* Monophasic (n  107) Biphasic (n  96) p Value
Age 65  13 (20–86) 65  14 (25–87) 0.86
Gender 0.65
Female 34 (32%) 27 (28%)
Male 73 (68%) 69 (72%)
Weight (kg) 88  24 (50–173) 87  19 (51–162) 0.70
NYHA class of congestive heart failure 0.93
None 74 (69%) 66 (69%)
I 10 (9%) 11 (11%)
II 15 (14%) 14 (15%)
III 7 (7%) 5 (5%)
IV 1 (1%) 0 (0%)
Ejection fraction 1.00
Normal (55%) 41/70 (59%) 44/71 (62%)
Mild impairment (40%–55%) 18/70 (26%) 11/71 (15%)
Moderate impairment (25%–39%) 9/70 (13%) 13/71 (18%)
Severe impairment (25%) 2/70 (3%) 3/71 (4%)
LA diameter (cm) 4.8  0.7 (3.0–6.1), 45 4.8  0.8 (3.2–6.5), 41 0.69
Cause of heart disease
Ischemic 20 (19%) 23 (24%) 0.39
Idiopathic dilated cardiomyopathy 7 (7%) 4 (4%) 0.54
Hypothyroidism 4 (4%) 5 (5%) 0.74
Alcoholic 6 (6%) 7 (7%) 0.78
Valvular 23 (21%) 19 (20%) 0.86
Hypertension 31 (29%) 33 (34%) 0.45
Medications
ACE inhibitor 36 (34%) 34 (35%) 0.88
Digoxin 40 (37%) 41 (43%) 0.47
Diuretic 49 (46%) 51 (53%) 0.33
Calcium channel blockers 27 (25%) 33 (34%) 0.17
Beta-blocker 45 (42%) 32 (33%) 0.25
Class I/III antiarrhythmic 54 (50%) 44 (46%) 0.57
Duration of current AF episode 0.39
48 h 11/86 (13%) 10/77 (13%)
48 h to 6 months 51/86 (59%) 51/77 (66%)
6 months to 1 year 15/86 (17%) 11/77 (14%)
1 year 9/86 (10%) 5/77 (6%)
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; LA  left atrial; *n  entire population of the column, except
where given explicitly as a denominator for a count, or after the range for a mean; NYHA  New York Heart Association.
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RESULTS
Patient population. The study enrolled 210 patients for
212 procedures at 11 sites between March 3, 1999, and
March 29, 2000. In two cases a patient was enrolled twice,
and the second procedure was excluded. One patient was
excluded due to incorrect electrode placement, and six
patients were excluded due to later assessment that the
original rhythm was not AF. The remaining 203 cases are
analyzed here.
Patient characteristics and demographic data were similar
between the treatment groups (Table 1). There was no
difference in age, gender, weight, New York Heart Associ-
ation (NYHA) congestive heart failure class, ejection frac-
tion or LA size. Causes of heart disease and use of cardiac
medications were similarly distributed. The duration of AF
was similar, with just 13% of each group having AF of48 h.
Results of conversion. There was a significantly greater
probability of conversion with the biphasic waveform at
100 J (60% biphasic vs. 22% monophasic, p  0.0001), at
150 J (77% vs. 44%, p 0.0001) and at 200 J (through three
shocks: 90% vs. 53%, p  0.0001). After four shocks,
including repeat 200 J biphasic or escalation to 360 J
monophasic, the cumulative success was similar (91% bi-
phasic vs. 85% monophasic, p  0.29) (Table 2, Fig. 2).
Crossover occurred in 14% of the monophasic patients
versus 6% of the patients assigned to the biphasic defibril-
lator (p  0.10). The resultant sample is small, but it is of
interest that 9 of 15 patients who crossed-over to biphasic
were converted, while only 1 of the 6 who failed to convert
with biphasic shocks was converted when crossed-over to
monophasic cardioversion (p  0.15).
A significantly greater number of shocks and greater total
energy were delivered to the patients randomized to
monophasic shocks (Fig. 3). With the monophasic wave-
form, 2.8  1.2 shocks and 548  331 J were required,
compared with 1.7  1.0 shocks and 217  176 J for
biphasic shocks (p  0.0001 for both comparisons). Peak
currents were higher for monophasic than for biphasic
shocks at each energy setting (100 J: monophasic 22  3 A,
n  107, biphasic 19  4 A, n  96, p  0.0001; 150 J:
monophasic 28  4 A, n  83, biphasic 22  4 A, n  36,
p  0.0001; 200 J: monophasic 32  4 A, n  60, biphasic
Table 2. Cumulative Shock Success
Monophasic Biphasic p Value RR (95% CI)
Patients 107 96
1 shock (100 J) 24 (22%) 58 (60%) 0.0001 2.3 (1.6–3.8)
2 shocks (100, 150 J) 47 (44%) 74 (77%) 0.0001 1.9 (1.4–2.7)
3 shocks (100, 150, 200 J) 57 (53%) 86 (90%) 0.0001 2.1 (1.6–2.9)
4 shocks (monophasic: 100, 150, 200, 360 J 91 (85%) 87 (91%) 0.29 1.3 (0.7–1.9)
biphasic: 100, 150, 200, 200 J)
CI  confidence interval; RR  relative risk.
Figure 2. Cumulative success in conversion of atrial fibrillation, according to the number of shocks delivered per protocol. See text for details of protocol.
Greater success was observed using the biphasic waveform (hatched bar) with a total of one, two or three shocks (100 J, 150 J and 200 J). After the fourth
shock (repeat 200 J biphasic or 360 J monophasic [dashed bar]), there was no significant difference in conversion success. *p  0.0001.
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26  2 A, n  43, p  0.0001) and were particularly high
for monophasic 360 J shocks (44  4 A, n  54).
Assessment of the degree of skin burn was performed by
telephone interview (76%) or direct inspection (24%); no
significant difference in the degree of severity was observed
between the two follow-up methods. Biphasic shocks were
associated with less dermal injury (Fig. 4, p  0.0001).
Tenderness with erythema was present in 17% with bipha-
sic, compared with 41% after monophasic shocks. Blistering
or necrosis occurred in two patients, both of whom received
exactly four monophasic shocks. Further evidence for the
deleterious effect of high energy shocks in the monophasic
arm is apparent in the progressive tendency for skin tender-
ness (moderate or severe skin burn) with increasing energy
in that study arm (p  0.0006), an effect not evident in the
biphasic arm (p  0.77) (Table 3).
Multivariate analysis of significant predictors identified
by univariate analysis identified shock waveform (p 
0.0001), patient weight (p  0.0007), duration of current
AF episode (p 0.0008) and transthoracic impedance (p
0.005) as independent predictors of first shock success. Of
these, only duration of current AF episode (p 0.0001) and
transthoracic impedance (p  0.02) remained significant
predictors of success for patients treated with four or fewer
shocks from the initial device.
Overall, regardless of shock waveform, patients failing
first shock cardioversion weighed more (93  23 kg vs.
80  17 kg, p  0.0007) and had higher transthoracic
impedance (83  16 ohms vs. 71  19 ohms) than patients
successfully converted on the first shock and had longer
durations of AF (Table 4). The latter was true regardless of
treatment (monophasic, p  0.04, biphasic p  0.02, Table
4). When conversion within the initial four shocks was
considered, this tendency was no longer statistically signif-
icant.
Patients who failed cardioversion with the initially ran-
domized device (failing to convert with all four shocks) had
higher transthoracic impedances than those who were suc-
cessfully converted (86  13 vs. 77  19, p  0.04). This
influence was confined to the monophasic population;
among monophasic patients, transthoracic impedances were
higher for those who failed cardioversion in four or fewer
shocks (91  13 ohms vs. 79  19 ohms, p  0.02), while
among biphasic patients there was no difference (76 
6 ohms vs. 76  18 ohms, p  0.94).
There were no significant differences between the treat-
ment populations in ECG rhythms at 5 s or 10 s, at 1 min
or 5 min or 1 h after the shock, providing successful
cardioversion had occurred. After 1 h 68/70 (97%) of the
biphasic and 77/85 (91%) of the monophasic patients were
in sinus rhythm (p  0.11).
Median ST levels and ST deviations were200 V at all
Figure 3. Number of shocks and cumulative delivered energy for monophasic and biphasic shocks. As shown in panel A, a median of three shocks were
required using monophasic shocks, compared with a median of one shock for biphasic. Panel B demonstrates that the total energy delivered, likewise, was
less for biphasic shocks.
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time points measured (5 s, 10 s, 1 min, 5 min, 1 h postshock)
for both treatments. In 20 comparisons (2 leads  5 time
points  [levels or deviations]), no statistically significant
difference was seen.
DISCUSSION
This study demonstrates the advantages of biphasic shocks
over monophasic shocks in conversion of AF. In a double-
blind, randomized trial in well-matched populations, a
step-up protocol with biphasic shocks resulted in greater
cumulative success at energies of 100 J, 150 J and 200 J,
although success with the four shock protocol (through
biphasic repeat 200 J or monophasic 360 J) was similar. The
biphasic waveform also required fewer shocks and less
energy and produced less dermal injury.
The biphasic shock waveform was the strongest indepen-
dent predictor of initial shock success. Other independent
predictors were lower weight, shorter duration of AF
episode and lower transthoracic impedance, consistent with
findings in other studies with both monophasic (5,17) and
biphasic defibrillators (8). The only independent predictor
of success within the first four shocks was lower transtho-
racic impedance. The influence of transthoracic impedance
was restricted to the monophasic arm; it had no residual
effect in the four-shock protocol with the biphasic wave-
form.
Previous studies with biphasic cardioversion. Ricard et
al. (7) and Mittal et al. (8) previously compared biphasic and
monophasic shock waveforms for transthoracic conversion
of AF. The present study agrees with those studies in
demonstrating the superiority of biphasic shocks, but im-
portant methodological differences must be recognized. The
Ricard et al. study (7) was relatively small (57 patients),
involved only a single-center, employed anterolateral pad
placement and had only a two-step protocol (either 150 J to
360 J monophasic or fixed 150 J biphasic). The Mittal et al.
study (8) was multicenter and used pad placement similar to
that used here but with different shock protocols (100 J,
200 J, 300 J, 360 J monophasic vs. 70 J, 120 J, 150 J, 170 J
biphasic) and different biphasic waveform shape (“rectilin-
ear” first pulse). There are differences among the studies in
Table 3. Progressive Tendency for Skin Tenderness Within
Each Protocol, for Patients Having No Cross-Over or
Nonprotocol Shocks
Skin “Tenderness” Monophasic Biphasic
Patients with exactly:
1 shock (max 100 J) 2/22 (9%) 4/47 (9%)
2 shocks (max 150 J) 5/22 (23%) 2/14 (14%)
3 shocks (max 200 J) 2/8 (25%) 2/11 (18%)
4 shocks (monophasic: max 360 J
biphasic: max 200 J)
18/30 (60%) 0/1 (0%)
p Value 0.0006 0.77
Figure 4. Dermal injury for all patients enrolled, according to shock waveform delivered. Injury, defined as moderate (erythema with tenderness) or severe
(blistering) was more frequent in those receiving monophasic (dashed bar) shocks (p  0.0001). See text for further details. Hatched bar  biphasic.
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patient population as well, particularly in duration of AF,
which emerged in our study as an important predictor of
first shock success. While very few (7%) of the patients in
the Ricard et al. study (7) had brief AF, (defined as
7 days), it is unclear how many had longer-term AF
because all durations 7 days are considered “chronic.” The
classification in the Mittal et al. study (8) is similar to that
used here except that it does not separate patients with AF
of greater than one year. The Mittal et al. study (8) included
a higher proportion of patients with short (48 h) (19%,
compared with 13% here) and a lower proportion of patients
with long (6 months) (13%, compared to 25% here)
duration AF (p  0.007). This may, in part, account for the
small difference in four-shock efficacy between their bipha-
sic arm (94%) and that in the present study (91%). Finally,
neither of the previous studies was blinded, and neither
apparently used an independent event committee, both
potential sources of investigator bias.
Study limitations. Although the findings are consistent
with one report of experience with rectilinear biphasic shock
(Mittal et al. [8]), they may not apply to other devices that
employ alternate biphasic waveforms.
What protocol should be used clinically for biphasic
cardioversion of AF? Based on the present study and other
data (7,8), it is reasonable to consider what protocol is
appropriate for elective cardioversion of AF using a biphasic
shock waveform. Because there are no data demonstrating
that cardiac injury results from shock energies of up to 200 J
biphasic, one could consider using 200 J (the maximum
output on some biphasic devices) as the appropriate first
choice; in fact, this may be appropriate for patients with AF
1 year duration. On the other hand, 150 J appears to have
approximately 80% likelihood of success, so it represents a
reasonable compromise between the desire to limit any
possible deleterious energy effects on the myocardium and
the efficient accomplishment of conversion. Failure with
this first shock would warrant advancing to 200 J, however.
Finally, for AF of 48 h duration, a first shock of 100 J
could be justified, as it results in 80% conversion.
Independent of the initial energy selected, if 200 J is
unsuccessful in conversion, one may consider alternate
electrode placement. Although studies of the effect of
electrode placement have yielded mixed results (6,10), in
some cases changing the electrode position results in suc-
cessful conversion when previously unsuccessful (at least for
monophasic shocks) (11). Thus, after one or two failed
cardioversion attempts with 200 J biphasic waveform
shocks, one might consider changing the placement of
electrodes to an anterior location (high right parasternal/left
apical), administration of an antiarrhythmic agent before
repeat shock delivery, double shocks or even catheter car-
dioversion.
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